At the news
? BULLISHIMPACT 7/10 8-K filed Jun 30, 2026 at 07:00 ET
NovoCure announced that its Optune Pax device received CE Mark for the treatment of locally advanced pancreatic cancer, based on Phase 3 PANOVA-3 data showing a statistically significant 2.0-month improvement in median overall survival (16.2 vs 14.2 months) and a 6.1-month delay in pain progression. This European regulatory approval follows the February 2026 FDA clearance and paves the way for commercial launch in Germany in the coming weeks, expanding the addressable market.
- Optune Pax received CE Mark for locally advanced pancreatic cancer, concomitant with gemcitabine and nab-paclitaxel.
- Phase 3 PANOVA-3 trial (n=571) met primary endpoint with mOS of 16.2 months (HR=0.82, p=0.039) in ITT population.
- mITT population showed mOS of 18.3 months (HR=0.77, p=0.023).
- Median time to pain progression extended by 6.1 months (HR=0.74, p=0.027).
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access